Tuberous sclerosis, angiomyolipoma and kidney cancer — what the kidney risk really is

Not usually. The kidney tumour tuberous sclerosis causes most often is an angiomyolipoma, which is benign: it is not cancer, it does not invade neighbouring organs and it does not spread. Most people with tuberous sclerosis develop them, often several, and often in both kidneys. Renal cell carcinoma, which is true kidney cancer, does occur in tuberous sclerosis, and it tends to appear at a younger age than it does in the general population. But it remains far less common than angiomyolipoma. So the honest answer is that tuberous sclerosis raises the risk of kidney cancer without making it likely, and for most people the day-to-day kidney concern is bleeding from a large angiomyolipoma rather than cancer.

No. An angiomyolipoma is a benign tumour built from fat, abnormal blood vessels and muscle-like tissue. It does not invade the organs around it and it does not spread elsewhere in the body. Because it contains fat, a radiologist can usually recognise it confidently on a CT or MRI scan, which is why these tumours are rarely a diagnostic puzzle and often need no biopsy. What makes them worth watching is not cancer risk but their blood vessels, which are abnormally formed and become more fragile as the tumour enlarges. That is why size and growth, rather than appearance, drive the decision about whether to treat one.

Because the gene change is present from birth in every cell of the body, not just in one kidney cell. Tuberous sclerosis is caused by an alteration in one of two genes that normally act as brakes on a growth-signalling pathway inside cells. With one brake weakened everywhere, tumours can start independently in many places at the same time. That is why kidney tumours in tuberous sclerosis are typically multiple and present on both sides, rather than the single tumour in one kidney that is usual when a kidney tumour arises by chance. The same mechanism explains why findings in the skin, brain, heart and lungs often appear alongside the kidney ones.

Regularly, and for life, though the interval is set by your team rather than by a rule you can look up. Specialist tuberous sclerosis surveillance guidance recommends periodic imaging of the abdomen, with MRI generally preferred because it shows these tumours well and avoids repeated radiation, alongside checks of blood pressure and kidney function. How often depends on how large the tumours already are, how quickly they have changed between scans, and whether anything has already been treated. Monitoring imaging and kidney-function review are arranged in-house at CION, and each scan is read against the previous one rather than on its own.

Almost always, yes, and preserving working kidney tissue is the priority in tuberous sclerosis precisely because the tumours are usually on both sides. Two approaches dominate. Drug treatment with an mTOR inhibitor acts on the very pathway that tuberous sclerosis leaves switched on, and can reduce the size of these tumours while the kidney stays intact; that is medical-oncology led and given in-house at CION. Where a tumour has already bled, or is judged too large to leave alone, blocking off its blood supply from inside the vessel or removing only the tumour is coordinated with specialist interventional radiology and urology partner centres. Removing a whole kidney is a last resort.

No. Many people with tuberous sclerosis are the first in their family to have it: the gene change arose new in them rather than being passed down, so there is no family history to find. Where it has been inherited, a single altered copy of the gene is enough to cause the condition, so it can pass from an affected parent to a child. Features vary widely even within one family, so one relative may have obvious skin or brain findings while another has little more than kidney tumours. That is why genetic counselling looks at the whole family carefully, and why an unremarkable family history never rules tuberous sclerosis out.